In an interventional clinical trial study, the autoantibodies to vimentin are being assessed as outcomes for the use of therapeutic plasma exchange, Rituximab, and IV IgG in the patients with severe acute exacerbation of IPF admitted in ICU (NCT03584802). The gene discussed is VIM; the disease is idiopathic pulmonary fibrosis.